Clinical trials: Transplant Failure
Type 1 Diabetes Mellitus
B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control.
- Trial name
- NCT01049633
- Testing
- Allogeneic Pancreatic Islet Cells, Sirolimus, Basiliximab
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Limbal Deficiency
Cell Therapy in Failure Syndromes in Limbal Stem Cells
Transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders in eyes with total limbal deficiency. Prospective non-comparative monocentric study.
- Trial name
- TC181 (NCT01619189)
- Testing
- epithelial stem cells cultured, transplantation of cultured cells
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Transplant; Failure, Kidney, EBV
Belatacept 3 Month Post Transplant Conversion Study
This study is being done to investigate the impact of changing immunosuppressive medications from tacrolimus (Prograf®) to belatacept (Nulojix®) between three (3) and six (6) months after kidney transplantation.
- Trial name
- NCT02213068
- Testing
- belatacept, Tacrolimus, MPA
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Lorenzo Gallon
Refractory Heart Failure
Levacor™ Ventricular Assist Device (VAD) Bridge to Transplant Study
The Levacor™ Ventricular Assist Device (VAD) has been designed for mechanical circulatory support in heart failure patients. The purpose of this clinical study is to determine its safety and efficacy as a bridge to transplant…
- Trial name
- NCT01001793
- Testing
- Levacor Ventricular Assist Device
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- World Heart Corporation
End-Stage Kidney Disease
Transplantation of Uncontrolled DCD Kidneys REconditioned by a Novel Ex-VIVo Perfusion MEthod
Eight patient will be transplanted with kidneys from donors dying after uncontrolled circulatory arrest (uDCD), with prolonged warm ischemia (up to 4,5 hours), preserved by a new method based on removal of fibrinogen/fibrin in…
- Trial name
- REVIVEME (NCT05703633)
- Testing
- uDCD treatment
- Volunteers
- 8 people
- Sponsor
- Sahlgrenska University Hospital
Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Trajectories of FEV1 After Lung Transplantation
For individuals with ESLD, lung transplantation is the best, or only treatment option with increased pulmonary function and quality of life.
- Trial name
- TRAJLUNG (NCT05934617)
- Where
- France
- Volunteers
- 2,500 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Transplant Failure
NCAMR-CAMR Allosure Study
Heart Transplant recipients at Tampa General Hospital heart transplant program who have pAMR1(H+) or pAMR1(I+) rejection will have a DD-cfDNA /GEP sample obtained at the time of the rejection.
- Trial name
- NCT04217343
- Testing
- Allosure/Allomap/Cytokines testing
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Tampa General Hospital
Organ Transplant Failure or Rejection, Brain Death
Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney delaYed Graft Function (CINERGY)
The investigators hypothesize that preconditioning neurologically deceased organ donors with the calcineurin inhibitor tacrolimus will improve short and long-term transplant survival without causing harm.
- Conditions
- Organ Transplant Failure or Rejection, Brain Death, Ischemic Reperfusion Injury
- Trial name
- CINERGY (NCT05148715)
- Testing
- Tacrolimus
- Where
- 9 sites in Canada
- Volunteers
- 414 people
- Sponsor
- Université de Sherbrooke
Multiple Myeloma, Blood Stem Cell Transplant Failure
Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies
This is a retrospective observational cohort database analysis. The study will review retrospectively the records of patients undergoing a first peripheral blood stem cell mobilization for multiple myeloma in the databases from…
- Trial name
- MOZOBIL (NCT02997813)
- Where
- 9 sites in France
- Volunteers
- 112 people
- Sponsor
- Intergroupe Francophone du Myelome
Liver Failure
A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation
This is a 24-month, Phase II, multi-center, two-arm, randomized controlled study of adult patients receiving a single organ liver transplant from a deceased donor; the purpose being to determine the efficacy of Thymoglobulin®…
- Trial name
- NCT02544113
- Testing
- Thymoglobulin
- Where
- 4 sites in United States
- Volunteers
- 110 people
- Sponsor
- The Cleveland Clinic
Aplastic Anemia
Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia
OBJECTIVES: I. Compare outcome, including graft failure, graft versus host disease, and survival of HLA-identical sibling bone marrow transplants for aplastic anemia using cyclophosphamide with or without antithymocyte globulin…
- Trial name
- NCT00004474
- Testing
- Anti-thymocyte globulin, Cyclophosphamide, Bone marrow transplantation
- Where
- 4 sites in United States
- Volunteers
- 224 people
- Sponsor
- Roswell Park Cancer Institute
Fanconi Anemia
Stem Cell Transplantation for Fanconi Anemia
The purpose of this study is to determine whether thymic shielding during total body irradiation can be given and whether it will reduce the risk of infections in Fanconi Anemia patients undergoing alternate donor (not a matched…
- Trial name
- NCT00167206
- Testing
- Hematopoietic Stem Cell Transplant, Thymic Shielding During Radiation, Total Body Irradiation
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Transplant; Failure, Kidney, Renal Disease, End Stage
Oral Paricalcitol in Kidney Transplant Recipients
This study is being done to find out whether patients who receive a kidney transplant can benefit from taking the medication paricalcitol (trade name Zemplar®) as compared to kidney transplant recipients not taking this…
- Conditions
- Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
- Trial name
- NCT00587158
- Testing
- Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Kidney Transplant Failure and Rejection, Pediatric Kidney Disease
Risk Assessment Tool for Graft Survival in Pediatric Kidney Transplantation
Registry study in which data of all pediatric kidney recipients in the Netherlands (registered in the Nederlandse Orgaan Transplantatie Registry) are studied to develop a risk calculator for graft loss.
- Trial name
- NCT05388955
- Testing
- None, transplantation recipients
- Volunteers
- 1,425 people
- Sponsor
- Radboud University Medical Center
Arteriovenous Graft, Arteriovenous Fistula
Validation of Arterio Venous Access Stage (AVAS) Classification
VAVASC trial is an observational multicentre study. The aim of this trial is to validate AVAS (arteriovenous vascular access stage) classification.
- Conditions
- Arteriovenous Graft, Arteriovenous Fistula, Dialysis Access Malfunction, Kidney Failure
- Trial name
- VAVASC (NCT04796558)
- Testing
- AVAS Classification
- Where
- Czechia
- Volunteers
- 800 people
- Sponsor
- Vascular surgery, University hospital Královské Vinohrady, Prague
End Stage Kidney Disease
Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation
This study will assess the safety and efficacy of IdeS in the transplantation setting. Each patient will receive one dose of IdeS.
- Trial name
- NCT02475551
- Testing
- IdeS
- Where
- Sweden
- Volunteers
- 10 people
- Sponsor
- Hansa Biopharma AB
Liver Transplant Failure, Prognostic Biomarkers
Serum GLYcomics to Predict Graft Loss and Mortality After Liver Transplantation
The first 12 months after liver transplantation (LT) are decisive in posttransplant outcome, as almost half of deaths and two thirds of graft loss requiring retransplant occur in the first year after LT.
- Trial name
- GLYGALT (NCT05866796)
- Testing
- GlycoTransplantTest
- Where
- Belgium
- Volunteers
- 600 people
- Sponsor
- University Hospital, Ghent
Non-Neoplastic Hematologic and Lymphocytic Disorder
Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
This phase II clinical trial studies how well treosulfan and fludarabine phosphate with or without low dose radiation before donor stem cell transplantation works in treating patients with nonmalignant (noncancerous) diseases.
- Trial name
- NCT00919503
- Testing
- Allogeneic Bone Marrow Transplantation, Anti-Thymocyte Globulin, Cyclosporine
- Where
- 6 sites in United States
- Volunteers
- 98 people
- Sponsor
- Fred Hutchinson Cancer Center
Corneal Sensation Reduced, Corneal Dystrophy
Defining the Operating Parameters for a Rebound-esthesiometer
The purpose of this study is to define the operating parameters for a new method to measure corneal sensitivity.
- Conditions
- Corneal Sensation Reduced, Corneal Dystrophy, Corneal Degeneration, Corneal Transplant Failure
- Trial name
- NCT04384094
- Testing
- Esthesiometer measurement
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Icare Finland Oy
Hematologic Malignancy, Bone Marrow Transplant
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
The purpose of this study is to evaluate the safety of reducing and ultimately eliminating anti-thymocyte globulin (ATG) from the haplo-cord transplant conditioning regimen and replacing it with tocilizumab, an IL-6 receptor…
- Trial name
- NCT04395222
- Testing
- Tocilizumab, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Weill Medical College of Cornell University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.